Evommune
Evommune raises $50M Series B at $300M valuation
Quick Facts
Evommune: Series B Funding Round
Evommune has successfully raised $50M in Series B funding, reaching a valuation of $300M.
Company Overview
Oral immunology treatments
Funding Details
The Series B round was led by Arix Bioscience, with participation from EQT Life Sciences.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2021
- Employees: 70+
- Category: HealthTech
Investment
Evommune plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arix Bioscience: Verified investor in Series B
- EQT Life Sciences: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
